The pharmaceutical giant is selling debt in eight parts, according to a person familiar with the matter, to help fund its purchase of Seagen. The longest portion of the deal, a 40-year bond, is expected to yield 1.8 percentage points over Treasuries, said the person, who asked not to be identified as the transaction is private.
